- Home
- BY vs NRIX Comparison
BY vs NRIX Comparison
Compare BY & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- NRIX
- Stock Information
- Founded
- BY 1914
- NRIX 2009
- Country
- BY United States
- NRIX United States
- Employees
- BY N/A
- NRIX N/A
- Industry
- BY Major Banks
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- NRIX Health Care
- Exchange
- BY Nasdaq
- NRIX Nasdaq
- Market Cap
- BY 1.2B
- NRIX 1.3B
- IPO Year
- BY 2017
- NRIX 2020
- Fundamental
- Price
- BY $31.10
- NRIX $22.92
- Analyst Decision
- BY Hold
- NRIX Strong Buy
- Analyst Count
- BY 3
- NRIX 15
- Target Price
- BY $30.67
- NRIX $29.33
- AVG Volume (30 Days)
- BY 219.3K
- NRIX 953.2K
- Earning Date
- BY 10-24-2024
- NRIX 10-11-2024
- Dividend Yield
- BY 1.16%
- NRIX N/A
- EPS Growth
- BY 6.38
- NRIX N/A
- EPS
- BY 2.76
- NRIX N/A
- Revenue
- BY $373,634,000.00
- NRIX $56,424,000.00
- Revenue This Year
- BY N/A
- NRIX N/A
- Revenue Next Year
- BY $3.13
- NRIX $7.17
- P/E Ratio
- BY $11.29
- NRIX N/A
- Revenue Growth
- BY 9.77
- NRIX N/A
- 52 Week Low
- BY $19.70
- NRIX $5.65
- 52 Week High
- BY $32.53
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- BY 64.46
- NRIX 38.26
- Support Level
- BY $26.15
- NRIX $26.48
- Resistance Level
- BY $32.53
- NRIX $29.56
- Average True Range (ATR)
- BY 0.94
- NRIX 1.56
- MACD
- BY 0.32
- NRIX -0.19
- Stochastic Oscillator
- BY 77.59
- NRIX 0.52
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium-sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to our customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.